Auryxia: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 234 stage 3-5 non-dialysis-dependent CKD patients who did not adequately respond to or tolerate current oral iron therapies showed that oral Auryxia met the primary endpoint of

Read the full 372 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE